In a 2013 study, Gu et al.[13] found that MARK2 enhances tau phosphorylation in vitro  and reported certain interactions between MARK2 and tau in the brain tissue of postmortem patients with Alzheimer's disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.